株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

モンテルカストAPIの世界市場:2023年までの予測

Global Montelukast API Market Research Report Forecast to 2023

発行 Market Research Future 商品コード 908213
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
モンテルカストAPIの世界市場:2023年までの予測 Global Montelukast API Market Research Report Forecast to 2023
出版日: 2019年07月31日 ページ情報: 英文 94 Pages
概要

世界のモンテルカストAPI市場は、2018年から2023年までの間に3.23%のCAGRで成長する見通しで、2023年には14億3,021万5,200ドルに達すると予測されています。喘息治療の需要、アレルギー性鼻炎の増加は、同市場の成長を後押しする要因に挙げられます。

当レポートは世界のモンテルカストAPI市場について調査しており、市場機会、成長および阻害要因、用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

  • 市場の魅力分析
    • 用途別
    • 地域別

第2章 市場の紹介

  • 定義
  • 調査範囲
  • 市場構造

第3章 調査方法

  • 調査方法
  • 一次調査
  • 二次調査
  • 市場規模の推計
  • 予測モデル
  • 仮定のリスト

第4章 市場力学

  • イントロダクション
  • 成長要因
  • 阻害要因
  • 市場機会

第5章 市場要因分析

  • サプライチェーン分析
  • ポーターのファイブフォース分析
  • 規制シナリオ
  • パイプライン分析
  • 価格の進展
  • 特許分析

第6章 世界市場:用途別

  • イントロダクション
  • 喘息
  • アレルギー性鼻炎
  • 気管支痙攣
  • じんましん
  • その他

第7章 世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • ラテンアメリカ
  • 欧州
    • スペイン
    • フランス
    • 英国
    • ドイツ
    • イタリア
    • 東欧
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • 中東・アフリカ
    • 中東
    • アフリカ

第8章 競争環境

  • イントロダクション
  • 主要開発分析

第9章 企業プロファイル

  • Merck Sharp & Dohme Corp
  • Dr. Reddy's Laboratories Ltd
  • Morepen Laboratories Ltd
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Glenmark
  • Sandoz International GmbH
  • Vintage Pharmaceuticals Inc
  • Hetero
  • Aurobindo Pharma

第10章 結論

  • 主な調査結果
図表

List of Tables

  • TABLE 1 LIST OF ASSUMPTIONS
  • TABLE 2 ATORVASTATIN API MARKET: PIPELINE ANALYSIS
  • TABLE 3 PRICING EVOLUTION (2015-2018), BY REGION (USD PER KG)
  • TABLE 4 PATENT ANALYSIS FOR THE GLOBAL DULOXETINE API MARKET
  • TABLE 5 GLOBAL MONTELUKAST API, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 6 GLOBAL MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 7 GLOBAL MONTELUKAST API MARKET FOR ASTHMA, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 8 GLOBAL MONTELUKAST API MARKET FOR ASTHMA, BY REGION, 2016-2023 (TONS)
  • TABLE 9 GLOBAL MONTELUKAST APIMARKET FOR ALLERGIC RHINITIS, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 10 GLOBAL MONTELUKAST API MARKET FOR ALLERGIC RHINITIS, BY REGION, 2016-2023 (TONS)
  • TABLE 11 GLOBAL MONTELUKAST API MARKET FOR BRONCHOSPASM, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 12 GLOBAL MONTELUKAST APIMARKET FOR BRONCHOSPASM, BY REGION, 2016-2023 (TONS)
  • TABLE 13 GLOBAL MONTELUKAST API MARKET FOR URTICARIA, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 14 GLOBAL MONTELUKAST APIMARKET FOR URTICARIA, BY REGION, 2016-2023 (TONS)
  • TABLE 15 GLOBAL MONTELUKAST API MARKET FOR OTHERS, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 16 GLOBAL MONTELUKAST API MARKET FOR OTHERS, BY REGION, 2016-2023 (TONS)
  • TABLE 17 GLOBAL MONTELUKAST API MARKET, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 18 GLOBAL MONTELUKAST API MARKET, BY REGION, 2016-2023 (TONS)
  • TABLE 19 GLOBAL MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 20 GLOBAL MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 21 NORTH AMERICA MONTELUKAST API MARKET, BY COUNTRY, 2016-2023 (USD THOUSAND)
  • TABLE 22 NORTH AMERICA MONTELUKAST APIMARKET, BY COUNTRY, 2016-2023 (TONS)
  • TABLE 23 NORTH AMERICA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 24 NORTH AMERICA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 25 U.S. MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 26 U.S. MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 27 CANADA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 28 CANADA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 29 LATIN AMERICA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 30 LATIN AMERICA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 31 EUROPE MONTELUKAST API MARKET, BY COUNTRY, 2016-2023 (USD THOUSAND)
  • TABLE 32 EUROPE MONTELUKAST API MARKET, BY COUNTRY, 2016-2023 (TONS)
  • TABLE 33 EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 34 EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 35 SPAIN MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 36 SPAIN MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 37 FRANCE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 38 FRANCE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 39 UK MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 40 UK MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 41 GERMANY MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 42 GERMANY MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 43 ITALY MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 44 ITALY MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 45 EASTERN EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 46 EASTERN EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 47 REST OF EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 48 REST OF EUROPE MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 49 ASIA-PACIFIC MONTELUKAST API MARKET, BY COUNTRY, 2016-2023 (USD THOUSAND)
  • TABLE 50 ASIA-PACIFIC MONTELUKAST API MARKET, BY COUNTRY, 2016-2023 (TONS)
  • TABLE 51 ASIA-PACIFIC MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 52 ASIA-PACIFIC MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 53 CHINA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 54 CHINA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 55 INDIA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 56 INDIA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 57 JAPAN MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 58 JAPAN MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 59 REST OF ASIA-PACIFIC MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 60 REST OF ASIA-PACIFIC MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 61 THE MIDDLE EAST AND AFRICA MONTELUKAST API MARKET, BY REGION, 2016-2023 (USD THOUSAND)
  • TABLE 62 THE MIDDLE EAST AND AFRICA MONTELUKAST API MARKET, BY REGION, 2016-2023 (TONS)
  • TABLE 63 THE MIDDLE EAST AND AFRICA MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 64 THE MIDDLE EAST AND AFRICA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 65 MIDDLE EAST MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 66 MIDDLE EAST MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 67 AFRICA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • TABLE 68 AFRICA MONTELUKAST APIMARKET, BY APPLICATION, 2016-2023 (TONS)
  • TABLE 69 KEY DEVELOPMENTS OVERVIEW

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL MONTELUKAST API MARKET ANALYSIS BY REGION
  • FIGURE 3 GLOBAL MONTELUKAST API MARKET: MARKET STRUCTURE
  • FIGURE 4 RESEARCH PROCESS FOR MRFR
  • FIGURE 5 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 6 MARKET DYNAMICS OVERVIEW
  • FIGURE 7 DRIVERS IMPACT ANALYSIS
  • FIGURE 8 RESTRAINTS IMPACT ANALYSIS
  • FIGURE 9 SUPPLY CHAIN: GLOBAL MONTELUKAST API MARKET
  • FIGURE 10 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL MONTELUKAST API MARKET
  • FIGURE 11 GLOBAL MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (USD THOUSAND)
  • FIGURE 12 GLOBAL MONTELUKAST API MARKET, BY APPLICATION, 2016-2023 (TONS)
  • FIGURE 13 GLOBAL MONTELUKAST API MARKET, BY REGION, 2017 (VALUE %)
  • FIGURE 14 GLOBAL MONTELUKAST API MARKET BY REGION, 2016-2023 (TONS)
目次

Montelukast API Market Research Report - Global Forecast till 2023

Market Analysis

An orally offered leukotriene receptor antagonist that used widely for the treatment of asthma is Montelukast API. Respiratory problems related with the exercise-induced bronchospasm is prevented by the same. Also, the symptoms of hay fever and allergic rhinitis is relieved through this. The leukotrienes that are responsible for causing or worsening asthma and related allergies is blocked by this drug that works by reducing the inflammation in the airways.

The growing incidence of asthma is expected to lead the market graph. However, the availability of alternatives and unfavorable effects connected with montelukast are likely to detain the market graph.

The Global Montelukast API Market is anticipated to list a CAGR of 3.38% to reach USD 1,430,215.2 thousand by 2023. It is high in demand globally for asthma treatment. The growing rate of allergic rhinitis cases is boosting the growth of the segment expected to display the highest CAGR of 3.11% from 2018 to 2023.

North America considered for the largest market share of 39.25% in 2017, and the regional market is expected to list a CAGR of 3.12% during the forecast period. Asia-Pacific is expected to register the rapid CAGR. The China market is anticipated to list the maximum growth rate of 5.10% during the forecast period from 2018 to 2023. The Europe market is predictable to surpass USD 396,258 thousand by 2023. Growing incidence of asthma, COPD, and allergies are striving to the growth of the Montelukast API market in the region. The key contributor to the growth of the regional market is UK which is followed by France. Montelukast API Manufacturers, Pharmaceutical Companies, Contract Research Organizations, Contract Manufacturing Organizations are projected spectators.

Market segmentation

The Global Montelukast API Market is segmented in two parts, by Application and by region. By Application it's sub-divided into Asthma, Allergic Rhinitis, Bronchospasm, Urticaria and Others. By Region it is divided into six countries i.e.; North America covering 2 countries US and Canada, Latin America, Europe while also covering Germany, Italy, Eastern Europe, Spain, UK, the Rest of Europe, Asia-Pacific covering countries like India, China, Japan, Rest of Asia-Pacific, Middle East and Africa.

Regional analysis

Geographically, the Global Montelukast API Market is intersected into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Some major players in Montelukast API Market are: Sandoz International GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Dr. Reddy's Laboratories Ltd (India), Morepen Laboratories Ltd (India), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (Israel), Vintage Pharmaceuticals Inc (US), Hikma Pharmaceuticals PLC (UK), Glenmark (India), Merck Sharp & Dohme Corp (US), Sandoz International GmbH (Germany), Hetero (India) and Aurobindo Pharma (India).

Table of Contents

1 Executive Summary

  • 1.1 Market Attractiveness Analysis
    • 1.1.1 Global Montelukast API Market, By Application
    • 1.1.2 Global Montelukast API Market, By Region

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model
  • 3.6 List of Assumptions

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Increasing Incidence of Asthma
  • 4.3 Restraints
    • 4.3.1 Availability of Substitutes and Adverse Effects Associated with Montelukast
  • 4.4 Opportunities
    • 4.4.1 Opportunities Associated with the Technological Advancements

5 Market Factor Analysis

  • 5.1 Supply Chain Analysis
    • 5.1.1 Research and Development
    • 5.1.2 Production
    • 5.1.3 Distribution & Sale
    • 5.1.4 Post-Sale Review
  • 5.2 Porter's Five Forces Model
    • 5.2.1 Threat of New Entrants
    • 5.2.2 Intensity of Rivalry
    • 5.2.3 Threat of Substitutes
    • 5.2.4 Bargaining Power of Suppliers
    • 5.2.5 Bargaining Power of Buyers
  • 5.3 Regulatory Scenario
  • 5.4 Pipeline Analysis
    • 5.4.1 Introduction
    • 5.4.2 Montelukast 10 mg Tablet
    • 5.4.3 Montelukast Chewable 5 mg Tablets
    • 5.4.4 Montelukast buccal film
    • 5.4.5 Montelukast 10mg
  • 5.5 Pricing Evolution
  • 5.6 Patent Analysis
    • 5.6.1 Overview

6 Global Montelukast API Market, by Application

  • 6.1 Introduction
  • 6.2 Asthma
  • 6.3 Allergic Rhinitis
  • 6.4 Bronchospasm
  • 6.5 Urticaria
  • 6.6 Others

7 Global Montelukast API Market, by Region

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Latin America
  • 7.4 Europe
    • 7.4.1 Spain
    • 7.4.2 France
    • 7.4.3 UK
    • 7.4.4 Germany
    • 7.4.5 Italy
    • 7.4.6 Eastern Europe
    • 7.4.7 Rest of Europe

  • 7.5 Asia-Pacific
    • 7.5.1 China
    • 7.5.2 India
    • 7.5.3 Japan
    • 7.5.4 Rest of Asia-Pacific
  • 7.6 The Middle East and Africa
    • 7.6.1 Middle East
    • 7.6.2 Africa

8 Competitive Landscape

  • 8.1 Introduction
  • 8.2 Key Development Analysis

9 Company Profiles

  • 9.1 Merck Sharp & Dohme Corp
    • 9.1.1 Financial Overview
    • 9.1.2 Products/Services Offered
    • 9.1.3 Key Developments
    • 9.1.4 SWOT Analysis
    • 9.1.5 Key Strategies
  • 9.2 Dr. Reddy's Laboratories Ltd
    • 9.2.1 Financial Overview
    • 9.2.2 Products/Services Offered
    • 9.2.3 Key Developments
    • 9.2.4 SWOT Analysis
    • 9.2.5 Key Strategies
  • 9.3 Morepen Laboratories Ltd
    • 9.3.1 Financial Overview
    • 9.3.2 Products/Services Offered
    • 9.3.3 Key Developments
    • 9.3.4 SWOT Analysis
    • 9.3.5 Key Strategies
  • 9.4 Mylan N.V.
    • 9.4.1 Financial Overview
    • 9.4.2 Products/Services Offered
    • 9.4.3 Key Developments
    • 9.4.4 SWOT Analysis
    • 9.4.5 Key Strategies
  • 9.5 Teva Pharmaceutical Industries Ltd
    • 9.5.1 Financial Overview
    • 9.5.2 Products/Services Offered
    • 9.5.3 Key Developments
    • 9.5.4 SWOT Analysis
    • 9.5.5 Key Strategies
  • 9.6 Hikma Pharmaceuticals PLC
    • 9.6.1 Financial Overview
    • 9.6.2 Products/Services Offered
    • 9.6.3 Key Developments
    • 9.6.4 SWOT Analysis
    • 9.6.5 Key Strategies
  • 9.7 Glenmark
    • 9.7.1 Financial Overview
    • 9.7.2 Products/Services Offered
    • 9.7.3 Key Developments
    • 9.7.4 SWOT Analysis
    • 9.7.5 Key Strategies
  • 9.8 Sandoz International GmbH
    • 9.8.1 Financial Overview
    • 9.8.2 Products/Services Offered
    • 9.8.3 Key Developments
    • 9.8.4 SWOT Analysis
    • 9.8.5 Key Strategies
  • 9.9 Vintage Pharmaceuticals Inc
    • 9.9.1 Financial Overview
    • 9.9.2 Products/Services Offered
    • 9.9.3 Key Developments
    • 9.9.4 SWOT Analysis
    • 9.9.5 Key Strategies

  • 9.1 Hetero
    • 9.10.1 Financial Overview
    • 9.10.2 Products/Services Offered
    • 9.10.3 Key Developments
    • 9.10.4 SWOT Analysis
    • 9.10.5 Key Strategies
  • 9.11 Aurobindo Pharma
    • 9.11.1 Financial Overview
    • 9.11.2 Products/Services Offered
    • 9.11.3 Key Developments
    • 9.11.4 SWOT Analysis
    • 9.11.5 Key Strategies

10 Conclusion

  • 10.1 Key Findings
Back to Top